Gonadorelin
Clinical TrialsGonadorelin
A synthetic version of GnRH that stimulates the release of LH and FSH. Used in research for testosterone support, fertility, and hormonal regulation.
Dose
100 mcg
Route
SubQ injection, IV
Cycle
Variable, often 8-12 weeks in research contexts for hormonal support.
Storage
2°C to 8°C (refrigerator) away from light
What is Gonadorelin?
Gonadorelin is a synthetic decapeptide that is structurally and functionally identical to the naturally occurring gonadotropin-releasing hormone (GnRH). It acts on the anterior pituitary gland to stimulate the pulsatile release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). In research contexts, Gonadorelin is investigated for its roles in stimulating endogenous testosterone production, supporting fertility, and regulating hormonal axes. Its short half-life necessitates frequent or pulsatile administration to maintain consistent stimulation of the pituitary.
Key Benefits
- Testosterone support
- LH and FSH stimulation
- Fertility support
- Testicular function maintenance
- HPA axis regulation
Mechanism of Action
- Mimics natural GnRH
- Stimulates pituitary to release LH and FSH
- LH triggers testosterone production in testes
Best For
- Testosterone research
- Fertility research
- Post-cycle research
Body Systems
🐾 Griffin Says...
Molecular Information
Molecular weight
1182.32 g/mol
Length
10 amino acids
Type
Peptide hormone (synthetic GnRH)
Amino acid sequence
Pyr-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2
The N-terminal pyroglutamic acid (Pyr) and C-terminal amide (NH2) are important for its biological activity.
Pharmacokinetics
Time to peak
10-20 minutes (IV administration)
Half-life
0.083 h
Time to clear
Within 2-4 hours
Widely cited in pharmacology texts for GnRH analogs.
Research Indications
LH and FSH Stimulation
Gonadorelin effectively stimulates the pulsatile release of both luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the anterior pituitary, mimicking natural GnRH.
Fertility Support
Investigated for its role in supporting fertility by promoting spermatogenesis in males and follicular development in females, often in cases of GnRH deficiency.
Testicular Function Maintenance
In research settings, it is studied for maintaining or restoring testicular function and endogenous testosterone production, particularly in contexts where exogenous testosterone might suppress natural production.
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Stimulation of Endogenous Testosterone Production (Males) | 50-100 mcg | 2-3 times per week, or every 8-12 hours | Subcutaneous |
| Support of Spermatogenesis | 50-100 mcg | Every 8-12 hours (pulsatile administration) | Subcutaneous |
| Assessment of Pituitary-Gonadal Axis Function | 100 mcg | Single dose, with blood draws at specific intervals (e.g., 0, 30, 60, 90 minutes) | Intravenous |
| Ovulation Induction/Follicular Development (Females) | 5-20 mcg | Every 90 minutes (pulsatile administration using a pump) | Subcutaneous/Intravenous |
| Prevention of Testicular Atrophy during TRT (as an adjunct) | 50 mcg | 2-3 times per week | Subcutaneous |
For optimal mimicry of natural pulsatile GnRH release, researchers often discuss precise timing of administration. In some protocols, fixed times (e.g., every 8 or 12 hours) are used, while others may explore variable intervals.
Peptide Interactions
- Use Caution
Exogenous Androgens (e.g., Testosterone)
Concurrent administration of exogenous androgens can suppress endogenous GnRH release, potentially counteracting Gonadorelin's intended effects on LH/FSH and endogenous testosterone production.
- Avoid
GnRH Antagonists
GnRH antagonists directly block GnRH receptors on the pituitary, rendering Gonadorelin ineffective and potentially leading to profound suppression of gonadotropins.
- Monitor Combination
Estrogens (high doses)
High levels of estrogens can exert negative feedback on the hypothalamus and pituitary, potentially blunting the response to Gonadorelin. Monitoring of hormonal levels is important.
- Monitor Combination
Glucocorticoids
Chronic or high-dose glucocorticoid use can suppress the HPG axis, potentially altering the efficacy of Gonadorelin. Close monitoring of hormonal parameters is advised.
- Monitor Combination
Dopamine Agonists (e.g., Bromocriptine)
Dopamine agonists can inhibit prolactin secretion and may indirectly influence gonadotropin release. The interaction with Gonadorelin is complex and requires monitoring.
- Synergistic
Aromatase Inhibitors (AIs)
When used to increase endogenous testosterone, AIs prevent the conversion of testosterone to estrogen, which can enhance the overall effect on the HPG axis when Gonadorelin stimulates testosterone production.
How to Reconstitute
- 1Gather supplies: Gonadorelin vial, bacteriostatic water for injection, sterile syringe, alcohol wipes.
- 2Clean the rubber stopper of the Gonadorelin vial and the bacteriostatic water vial with alcohol wipes.
- 3Draw the desired amount of bacteriostatic water into the syringe (e.g., 1 mL for 1 mg vial).
- 4Slowly inject the bacteriostatic water into the Gonadorelin vial, aiming the stream against the vial's side.
- 5Gently swirl the vial to dissolve the peptide. Do not shake.
- 6Once fully dissolved and clear, the solution is ready for administration.
Reconstitute with bacteriostatic water for injection. Swirl gently; do not shake vigorously.
What to Expect
- Weeks 1-2: Initial stimulation of LH and FSH release. Some individuals may report subtle changes in well-being or energy.
- Weeks 3-6: More noticeable increases in endogenous testosterone production (for male subjects) and potential improvements in libido. Hormonal parameters may begin to stabilize.
- Weeks 7-12: Further optimization of hormonal balance and potential improvements in reproductive markers. Researchers may observe sustained elevations in LH, FSH, and testosterone.
- Months 3-6 (longer protocols): Continued assessment of long-term effects on testicular function, sperm parameters, and overall hormonal health, depending on research goals.
- Post-cycle: Monitoring of hormonal levels to assess the body's natural recovery and regulation after cessation of Gonadorelin administration.
Side Effects & Safety
| Effect | Frequency | Severity |
|---|---|---|
| Headache | Uncommon | Mild |
| Injection site irritation | Common | Mild |
| Nausea | Uncommon | Mild |
Ready to calculate your dose? Use Griffin's Peptide Calculator 🐾
Open CalculatorPeptides discussed here are for research purposes only. Nothing on this page is medical advice. Always consult a qualified professional before making health decisions.